AbbVie Operating Expenses 2010-2022 | ABBV

AbbVie annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • AbbVie operating expenses for the quarter ending June 30, 2022 were $11.288B, a 18.6% increase year-over-year.
  • AbbVie operating expenses for the twelve months ending June 30, 2022 were $39.957B, a 4.66% increase year-over-year.
  • AbbVie annual operating expenses for 2021 were $38.273B, a 11.13% increase from 2020.
  • AbbVie annual operating expenses for 2020 were $34.441B, a 69.8% increase from 2019.
  • AbbVie annual operating expenses for 2019 were $20.283B, a 23.08% decline from 2018.
AbbVie Annual Operating Expenses
(Millions of US $)
2021 $38,273
2020 $34,441
2019 $20,283
2018 $26,370
2017 $18,671
2016 $16,298
2015 $15,322
2014 $16,549
2013 $13,126
2012 $12,563
2011 $13,824
2010 $10,921
2009 $9,282
AbbVie Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $11,288
2022-03-31 $8,821
2021-12-31 $9,812
2021-09-30 $10,036
2021-06-30 $9,518
2021-03-31 $8,907
2020-12-31 $10,105
2020-09-30 $9,647
2020-06-30 $9,673
2020-03-31 $5,016
2019-12-31 $4,748
2019-09-30 $5,862
2019-06-30 $4,855
2019-03-31 $4,818
2018-12-31 $10,746
2018-09-30 $5,077
2018-06-30 $5,516
2018-03-31 $5,031
2017-12-31 $5,957
2017-09-30 $4,301
2017-06-30 $4,282
2017-03-31 $4,131
2016-12-31 $4,482
2016-09-30 $4,071
2016-06-30 $4,065
2016-03-31 $3,680
2015-12-31 $4,287
2015-09-30 $4,059
2015-06-30 $3,623
2015-03-31 $3,353
2014-12-31 $5,867
2014-09-30 $4,059
2014-06-30 $3,411
2014-03-31 $3,212
2013-12-31 $3,576
2013-09-30 $3,287
2013-06-30 $3,239
2013-03-31 $3,024
2012-12-31 $3,385
2012-09-30 $2,912
2012-06-30 $3,071
2012-03-31 $3,195
2011-12-31 $10,751
2011-09-30
2011-06-30
2011-03-31 $3,072
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $247.976B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22